As the gene therapy pipeline builds and stop loss renewals become more competitive, traditional stop loss plans may not provide appropriate levels of coverage for smaller and mid-sized self-funded groups. Carriers may impose additional restrictions, such as rate increases, coverage exclusions, lasering and even non-renewals.
That’s why BCS launched Stop Loss GTS, a “carve out” stop loss policy for the gene therapy ingredient only, designed to sit alongside traditional stop loss.
Stop Loss GTS removes large gene therapy claims from the stop loss program and transfers it to a separate policy designed specifically for this purpose. This option can help to add predictability to unknown, catastrophic claims and protect against lasering, rate increases, non-renewals and more. Contact BCS today to learn more!
